Novanta Q3 Revenue Up 23% to $305M; Q4 EPS Guidance Flat at 0-5% Growth
NOVT sits 49% above its 52-week low of $98.27.
Summary
Novanta grew Q3 revenue 23% to $305M and Adjusted EBITDA 38% to $80.3M, but GAAP EPS fell to $0.05 and fourth-quarter EPS guidance implies only 0-5% growth.
Key Events · Earnings and Guidance · NOVT
-
Q3 Revenue Jumps 23% to $305M
GAAP revenue rose 23.1% to $305.0M from $247.8M, with acquisitions adding 13.3 points and organic growth at 9.9%.
-
GAAP EPS Collapses to $0.05
GAAP net income fell to $2.0M from $10.7M as $51.2M of non-GAAP adjustments — including $21.4M intangible amortization and $19.2M acquisition costs — drove Adjusted Diluted EPS up 21% to $1.05.
-
Q4 Guidance Shows Sharp Deceleration
Fourth-quarter Adjusted Diluted EPS is guided to $0.91-$0.96, or 0% to 5% growth, on revenue of $306-312M; full-year Adjusted Diluted EPS is guided to $3.66-$3.71.
-
Leverage Rises After Riverpoint Deal
Net debt stands at $689.4M versus net cash of $121.3M at December 31, 2025, after $1.2B paid for Riverpoint Medical and $626M drawn on the senior credit facilities.
Analysis · NOVT · Manufacturing
Revenue and adjusted profit beat the company's own expectations, but the headline numbers hide a wide GAAP-to-adjusted gap: $51.2M of adjustments (mostly acquisition amortization and deal costs) turned $2.0M of GAAP net income into $45.0M adjusted. The bigger issue for holders is the fourth-quarter guide, which calls for Adjusted Diluted EPS of $0.91-$0.96, or 0% to 5% growth — a sharp deceleration from the 21% just reported, and the reason this quarter's beat may not carry the stock. Balance sheet leverage is now real: net debt of $689.4M after the $1.2B Riverpoint deal, versus net cash of $121.3M at the start of the year.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NOVT was trading at $146.00 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $98.27 to $176.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.